Status:
RECRUITING
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
Nephrotic Syndrome
Rituximab
Eligibility:
All Genders
1-18 years
Brief Summary
This was a retrospective study. Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab (RTX) and followed up for ≥1 year in the Department of Pediatrics, the First A...
Eligibility Criteria
Inclusion
- Children clinically diagnosed with FRNS/SDNS/SRNS with complete clinical data;
- age \< 18 years old;
- For the first time using RTX treatment, and used in nephrotic syndrome ease;
- The follow-up for 1 year or more.
Exclusion
- Congenital or infantile nephrotic syndrome, secondary nephrotic syndrome (such as lupus nephritis, IgA nephropathy, purpura nephritis, hepatitis B nephritis, etc.);
- Active stage of hepatitis, complicated with severe infection, severe deficiency of immune response, malignant diseases;
- Estimated glomerular filtration rate (GFR) \<60mL/min/1.73m2.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06530004
Start Date
March 1 2020
End Date
March 1 2028
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First affiliated hospital of xiamen university
Xiamen, Fujian, China, 361003